Clinical Trials Sponsored by Newron Pharmaceuticals S.p.A.

Total 49 results

Newron Pharmaceuticals SPA

Unknown

An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects

Healthy

United Kingdom
Newron Pharmaceuticals SPA

Completed

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

Schizophrenia

United States
Newron Pharmaceuticals SPA

Completed

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa (SETTLE)

Idiopathic Parkinson's Disease

Korea, Republic of, Israel, Thailand, New Zealand, Spain, Canada, United States, Switzerland, Netherlands, Taiwan, United Kingdom, Belgium, Estonia, Germany, Hungary, India, Australia, Austria, France, Malaysia, Slovakia
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

Idiopathic Parkinson's Disease

Italy
Newron Pharmaceuticals SPA

Completed

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

Schizophrenia

India, United States
Newron Pharmaceuticals SPA

Completed

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease With Cognitive Impairments

Spain, United States
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Parkinson's Disease
Newron Pharmaceuticals SPA

Terminated

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms (STARS)

Rett Syndrome

United States, India, United Kingdom, Australia, Italy
Newron Pharmaceuticals SPA

Terminated

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Romania
Newron Pharmaceuticals SPA

Terminated

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Parkinson Disease

United States
Newron Pharmaceuticals SPA

Completed

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Chronic Schizophrenia

United States, India
Newron Pharmaceuticals SPA

Completed

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)

Idiopathic Parkinson's Disease

United States, Spain, Brazil, Peru, Colombia, Germany, Argentina, India, Croatia, Czech Republic, Italy, South Africa, Finland, Portugal, Canada, Slovakia, Bulgaria, Chile, Mexico, Poland
Newron Pharmaceuticals SPA

Completed

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects (Safinamide-LID)

Parkinson's Disease

Austria, Canada, France, Germany, South Africa
Newron Pharmaceuticals SPA

Terminated

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) (MOTION)

Idiopathic Parkinson's Disease

Switzerland
Newron Pharmaceuticals SPA

Completed

Safinamide Renal Impairment Trial

Renal Impairment

Germany
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Newron Pharmaceuticals SPA

Completed

Phase II Dose Titration Study in Patients With Neuropathic Pain

Neuropathic Pain

United Kingdom, Czech Republic, Poland, Italy, India, Austria
Newron Pharmaceuticals SPA
Parexel; CliniRx

Completed

Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

Pain

United Kingdom
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001)

Prader-Willi Syndrome

United States
Nephron Pharmaceuticals Corporation

Completed

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Neuren Pharmaceuticals Limited

Completed

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

Fragile X Syndrome

United States
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Female Subjects

Brain Injuries, Traumatic

Australia
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) (PTHS-001)

Pitt Hopkins Syndrome

United States
Neuren Pharmaceuticals Limited

Terminated

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Concussion

United States
Neuren Pharmaceuticals Limited

Completed

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

Brain Injuries, Traumatic

Australia
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)

Angelman Syndrome

Australia
Neuren Pharmaceuticals Limited

Active, not recruiting

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) (PMS-001)

Phelan-McDermid Syndrome

United States
Neuren Pharmaceuticals Limited

Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

Healthy Volunteers

Australia
Neuren Pharmaceuticals Limited

Completed

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC (INTREPID2566)

Brain Injuries

United States
Neuren Pharmaceuticals Limited

Completed

Study of NNZ-2566 in Patients With Traumatic Brain Injury (INTREPID2566)

Brain Injuries

United States
Neuren Pharmaceuticals Limited
rettsyndrome.org

Completed

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Rett Syndrome

United States
sigma-tau i.f.r. S.p.A.
SciClone Pharmaceuticals

Completed

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Chronic Hepatitis C

Spain, Italy, France, Germany, Greece
International Biomedical Systems S.p.A.
CSC Pharmaceuticals

Unknown

Numen Stent Assessment Using OCT Technique in a Single Center Study (NAUTIC)

Hyperplasia | Restenosis

Austria
Lee's Pharmaceutical Limited
Fidia Farmaceutici s.p.a.

Completed

Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness

The Primary Objective of This Study Was to Assess the Efficacy and Safety of Hyaluronic Acid Vaginal Gel in Treating Vaginal Dryness
Nephron Pharmaceuticals Corporation
Rho, Inc.

Completed

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Indonesia University
Ferron Par Pharmaceuticals

Completed

Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery

Cataract

Indonesia
HanAll BioPharma Co., Ltd.
NurrOn Pharmaceuticals, Inc.

Completed

A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants

Healthy Volunteers

Canada
SPA Società Prodotti Antibiotici S.p.A.
Pharmaceutical Development and Services

Recruiting

Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients

Osteoarthritis of Knee

Italy
Regeneron Pharmaceuticals
Pacific Pediatric Neuro-Oncology Consortium

Terminated

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

High Grade Glioma | Diffuse Intrinsic Pontine Glioma | Relapsed Solid Tumor | Refractory Solid Tumor | Relapsed Central Nervous System Tumor | Refractory Central Nervous System Tumor

United States
Lundbeck Italia S.p.A.
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn (ACCORDO)

Parkinson's Disease | Depressive Symptoms

Italy
Caleb Nelson
Otsuka America Pharmaceutical

Completed

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study (TCUPS)

Cystinuria

United States
Neuren Pharmaceuticals Limited
Baylor College of Medicine; International Rett Syndrome Foundation

Completed

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Rett Syndrome

United States
APR Applied Pharma Research s.a.
Cavendish Impact Foundation; Clinigen, Inc.; Nephron Pharmaceuticals, Inc.

No longer available

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) (SAMICARE)

Critical COVID-19 With Respiratory Failure

United States
University of California, San Francisco
Novartis Pharmaceuticals; Pacific Pediatric Neuro-Oncology Consortium; The Pediatric...

Active, not recruiting

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Pediatric Recurrent Progressive Low-grade Gliomas | Pediatric Progressive Low-grade Gliomas

United States
Chiesi Farmaceutici S.p.A.
University of Pisa; Fondazione Don Carlo Gnocchi Onlus; Universita degli Studi... and other collaborators

Completed

Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Italy
Paul Richardson, MD
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts... and other collaborators

Active, not recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

Multiple Myeloma

United States

Clinical Trials Sponsored by Newron Pharmaceuticals S.p.A.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations